HOUSE CONCURRENT RESOLUTION

URGING THE UNITED STATES CONGRESS TO KEEP THE AMERICAN PEOPLE SAFE AND HEALTHY BY DECREASING THE NATION'S DEPENDENCY ON FOREIGN MANUFACTURED PHARMACEUTICAL INGREDIENTS AND MEDICINE, PARTICULARLY FROM CHINA

WHEREAS, millions of Americans depend on pharmaceutical drugs to cure, treat, or prevent disease and these drugs can result in lifesaving and life sustaining outcomes; and

WHEREAS, China has become the world's largest supplier of active pharmaceutical ingredients and the U.S. Food and Drug Administration estimates that at least eighty per cent of active pharmaceutical ingredients are manufactured outside of the United States, mainly in China; and

WHEREAS, China's dominance in supplying the United States' chemical and pharmaceutical sector has driven out many U.S. based pharmaceutical companies resulting in a loss of capacity to domestically produce vital drugs used by patients every day; and

WHEREAS, the increased dependence on Chinese produced active pharmaceutical ingredients creates a national security risk and public health risk that cannot be overstated, as it results in U.S. dependence on foreign-sourced pharmaceuticals; and

WHEREAS, due to America's dependence on Chinese produced active pharmaceutical ingredients, China could weaponize its position in the pharmaceutical supply chain to the disadvantage and peril of the citizens of the United States by manipulating or cutting off the supply of active pharmaceutical ingredients; now, therefore,

BE IT RESOLVED by the House of Representatives of the Thirtieth Legislature of the State of Hawaii, Regular Session of 2020, the Senate concurring, the U.S. Congress is urged to decrease the nation's dependence on foreign manufactured medicines, particularly from China to ensure the continuity and safety of the supply of the products and keep the American people safe and healthy; and

· 8

BE IT FURTHER RESOLVED that the U.S. Congress is advised to develop a white paper on the methods, materials, and timeline necessary to phase out or reduce American dependence on the manufacture of active pharmaceutical ingredients by potentially hostile powers, such as China and Russia; and

BE IT FURTHER RESOLVED that the U.S. Congress is urged to incentivize the creation or reestablishment of American owned and operated active pharmaceutical ingredients factories in the United States; and

BE IT FURTHER RESOLVED that certified copies of this Resolution be transmitted to the President of the United States, the Vice President of the United States, the Speaker of the United States House of Representatives, the Minority Leader of the United States House of Representatives, the President of the United States Senate, the Secretary of Defense, the Secretary of State, the Office of the Surgeon General, the Centers for Disease Control, the U.S. Department of Health and Human Services, the Joint Chiefs Of Staff, Blue Cross Blue Shield Association, Kaiser Permanente, Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck & Co, AbbVie Inc, Bristol-Myers Squibb, Eli Lilly and Company, Biogen, Abbott Laboratories, Stryker Corporation, and Regeneron.

Cits

OFFERED BY:

Richally

HCR HMIA 2020-17-08

FEB 1 9 2020